Dr. Doug Lowy, interim director of the National Cancer Institute, recently visited the UK Markey Cancer Center, continuing a dialogue on cancer in Kentucky following his visit to Hazard, Ky. last fall.
Kentucky is home to the highest cancer incidence and mortality rates in the country, a major health problem that Markey is dedicated to changing. In July 2013, Markey received a prestigious NCI designation, which allows the center access to more research funding, trials and treatments.
Much of Lowy’s visit focused on research. Nine UK faculty members gave presentations on major research initiatives and programs at Markey, ranging from efforts in cancer prevention and control to drug development and discovery. Major topics of discussion centered around the cancer types that affect Kentuckians the most: lung cancer, colon cancer, cervical cancer/HPV and the hepatitis C virus, which is linked to liver cancer.
After meeting with a group of Markey junior faculty members, Lowy learned more about the UK HealthCare enterprise and its support of Markey from Dr. Michael Karpf, executive vice president for health affairs at UK. Lowy finished the day with a tour of clinical space in UK Albert B. Chandler Hospital’s Pavilion A – future home to Markey’s Hematology and Blood & Marrow Transplantation inpatient floor – and a dedicated cancer research lab in the UK College of Pharmacy.
“We were honored to have Dr. Doug Lowy visit us today at the UK Markey Cancer Center to learn more about our patients and the research we do here,” said Dr. Mark Evers, director of Markey. “It was a wonderful opportunity to engage with the NCI and with Dr. Lowy, so that they better understand some of the difficulties we have in delivering care to our patient population.”